IBDoc News | IBDoc

IBDoc® receive upgrades for a better experience!

We have sucessfully reached new milestones for IBDoc® ! As of May 26, 2024, IBDoc® is CE-marked as self-test and near-patient test under the new In Vitro Diagnostic Regulation (IVDR) regulation, taking the fecal calprotectin home test to new standards and improving the overall trust on our product. In addition, the software was completely redesigned and deployed […]

IBDoc® receive upgrades for a better experience! Read More »

Successful Integration of IBDoc^® into a Hospital Remote Monitoring System, using the standard HL7 communication pathway: Flarometer

An interview with Prof. Dr. Patrick Van RheenenUniversity Medical Center Groningen, The Netherlands Can you introduce yourself and your organization?My name is Patrick van Rheenen and work at the University Medical Centre in Groningen (the Netherlands). I am a clinical researcher into paediatric inflammatory bowel disease. How did you choose IBDoc® for the Flarometer project?Part of my research focusses on home telemonitoring.

Successful Integration of IBDoc^® into a Hospital Remote Monitoring System, using the standard HL7 communication pathway: Flarometer Read More »

Successful evaluation of IBDoc^® with IBD Home from Telia Company

IBDoc News, News / Christian Reinhard

IBDoc® is present in the market for 6 years now and its efficiency and usefulness has been described many times by different research teams all over the world (1, 2, 3). All of these papers are evaluating IBDoc® as a stand-alone product but IBDoc® has the possibility to be integrated in a 3rd party application,

Successful evaluation of IBDoc^® with IBD Home from Telia Company Read More »

COVID-19 impact on IBD centers: IBDoc^® success story and surveys

IBDoc News, News / Christian Reinhard

In 2020, the COVID-19 crisis had a high impact on the daily life of people all over the world. That is particularly true for patients with a chronic disease who must go to their hospital for regular follow-up visits. Inflammatory Bowel Disease (IBD) patients are no exception here. In order to face this extraordinary situation,

COVID-19 impact on IBD centers: IBDoc^® success story and surveys Read More »

The role of IBDoc^® in virtual clinics

IBDoc News, News / Christian Reinhard

In 2016, the Nancy University Hospital has set-up a virtual clinic for Inflammatory Bowel Disease (IBD) patients. The main goal of this eHealth solution is to provide a communication channel between patients and the healthcare professionals and to decide on patient management changes. In 2018, the IBD unit decided to add the possibility to perform

The role of IBDoc^® in virtual clinics Read More »

IBDoc^® in Clinical Practice

IBDoc News, News / Christian Reinhard

Fecal calprotectin is an ideal non-invasive marker to monitor inflammation in the gut for patients suffering from IBD. Since IBD is a chronic condition, remote disease monitoring offers patients to facilitate their disease management and working lives since less hospital visits are needed. Further, hospital visits always bear the risk of potential infections, not only

IBDoc^® in Clinical Practice Read More »

IBDoc^® News from ECCO 2020

IBDoc News, News / Christian Reinhard

At ECCO 2020, IBDoc® was again under the spotlight as 2 very interesting posters were presented. After 5 years of market presence, long term data about the impact of IBDoc® usage in clinical routine are beginning to emerge. Improving quality of life of IBD patients is extremely important, developing tools to allow patients to have

IBDoc^® News from ECCO 2020 Read More »

Fecal calprotectin- a small protein of high importance

IBDoc News, News / Christian Reinhard

Worldwide more than 6.8 million people live with Inflammatory Bowel Disease (IBD) which is characterized by chronic inflammation of the gastrointestinal tract. The highest numbers of IBD patients are observed in North America and Europe with an estimated 2.2 million affected persons in North America and an estimated 0.3% of the European population suffering from

Fecal calprotectin- a small protein of high importance Read More »

IBD and COVID-19

IBDoc News, News / Christian Reinhard

Because of the current situation with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 disease it is important to keep IBD patients out of clinics whenever possible. Nevertheless, tight monitoring of inflammation level in the gut is needed to deal with these chronic conditions. Calprotectin has proven to be an ideal

IBD and COVID-19 Read More »

Fecal Calprotectin Home Testing in 2020

IBDoc News, News / Christian Reinhard

The use of fecal calprotectin (fCAL) in clinical routine is demonstrated beyond doubt. We now have extensive knowledge of its efficacy for IBD/IBS differentiation and IBD monitoring, as it has been shown to be an excellent surrogate biomarker for inflammatory status of the gut that correlates well with endoscopic activities (1). The key benefit of

Fecal Calprotectin Home Testing in 2020 Read More »